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Abstract
Background: The clinical signs of active trachoma are often present in the absence of ocular Chlamydia trachomatis
infection in low prevalence and mass treated settings. Treatment decisions are currently based on the prevalence of clinical
signs, and this may result in the unnecessary distribution of mass antibiotic treatment. We aimed to evaluate the diagnostic
accuracy of a prototype point-of-care (POC) test, developed for field diagnosis of ocular C. trachomatis, in low prevalence
settings of The Gambia and Senegal.
Methodology/Principal Findings: Three studies were conducted, two in The Gambia and one in Senegal. Children under
the age of 10 years were screened for the clinical signs of trachoma. Two ocular swabs were taken from the right eye. The
first swab was tested by the POC test in the field and the result independently graded by two readers. The second swab was
tested for the presence of C. trachomatis by Amplicor Polymerase Chain Reaction. In Senegal, measurements of humidity
and temperature in the field were taken. A total of 3734 children were screened, 950 in the first and 1171 in the second
Gambian study, and 1613 in Senegal. The sensitivity of the prototype POC test ranged between 33.3–67.9%, the specificity
between 92.4–99.0%, the positive predictive value between 4.3–21.0%, and the negative predictive value between 98.0–
99.8%. The rate of false-positives increased markedly at temperatures above 31.4uC and relative humidities below 11.4%.
Conclusions/Significance: In its present format, this prototype POC test is not suitable for field diagnosis of ocular C.
trachomatis as its specificity decreases in hot and dry conditions: the environment in which trachoma is predominantly
found. In the absence of a suitable test for infection, trachoma diagnosis remains dependent on clinical signs. Under current
WHO recommendations, this is likely resulting in the continued mass treatment of non-infected communities.
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Introduction
Trachoma is caused by ocular infection with the bacterium
Chlamydia trachomatis and is the leading infectious cause of blindness
worldwide [1]. The World Health Organization (WHO) simplified
grading system, designed for the simple and reliable grading of
trachoma clinical signs by non-specialist staff, is predominantly
used for trachoma diagnosis in the field [2]. This system classifies
the clinical signs into five categories: trachomatous inflammation-
follicular (TF), trachomatous inflammation-intense (TI), tracho-
matous scarring (TS), trachomatous trichiasis (TT), and corneal
opacity (CO).
Clinical signs are however poorly correlated with detection of
ocular C. trachomatis infection, since they may persist for months or
yearsafterinfection hascleared [3,4,5,6,7].The WHO recommends
that any district or community where the prevalence of TF in
childrenaged1–9yearsisatleast10%shouldreceivemassantibiotic
treatment annually for three years, before the prevalence is re-
assessed [8]. Since antibiotics are given to treat C. trachomatis
infection, and the prevalence of clinical signs is a poor predictor of
infection especially in low prevalence and mass treated settings,
treatment may be unnecessarily commenced and continued, thus
wasting scarce resources. A point-of-care (POC) test capable of
detecting infection in the field would enable treatment to be directed
to those communities in need. Since a POC test would be used to
make treatment decisions at the community, rather than the
individual, level, it is important that it has high specificity (.98%),
otherwise it has no advantage over the use of clinical signs.
A prototype POC test for trachoma, developed by the
Diagnostics Development Unit (University of Cambridge, UK),
www.plosntds.org 1 August 2011 | Volume 5 | Issue 8 | e1234and currently not commercially available, has previously been
evaluated on a small scale in a medium prevalence Tanzanian
setting (12.5–37.9% TF in children aged 1–9 years), with
encouraging results [9]. This assay is a modified version of a test
for genital C. trachomatis infection [10,11], optimised for use with
conjunctival swabs. The assay detects the chlamydial lipopolysac-
charide (LPS),usinglateralflow technology.Thedipstickismade up
of a nitrocellulose membrane affixed to a backing sheet, and
connected to an absorbent pad, with two immobilised monoclonal
antibodies (mAbs) lined on the dipstick membrane. The mAb at the
capture line is against chlamydial LPS, and that at the procedural
control line is an antibiotin antibody. This assay was designed
specifically for use in resource-limited settings, and therefore has no
electricity, water or laboratory equipment requirements [9].
We aimed to conduct a larger scale evaluation of this prototype
POC test’s diagnostic accuracy in children aged under 10 years in
the low prevalence settings of The Gambia and Senegal. The
functional temperature and humidity range of the prototype test
was unknown before this study’s field testing.
Methods
The study has been reported in accordance with the STARD
(STAndards for the Reporting of Diagnostic accuracy studies)
checklist (provided as Supporting Information S1) [12].
Ethics statement
Research was done in accordance with the declaration of
Helsinki. Ethical approval was obtained from the London School
of Hygiene & Tropical Medicine (LSHTM) ethics committee
(No.2067), the Gambia Government/Medical Research Council
Joint Ethics Committee (SCC 979), and the Comite ´ d’e ´thique du
CNRS, Dakar, Senegal. Written (thumbprint or signature)
informed consent was obtained from the guardians of all children.
Study site and participant selection
Three studies were conducted, two in The Gambia and one in
Senegal. An overview of the study methods is depicted in Figure 1.
Study 1 was part of a survey of the Lower River (LRR) and North
Bank (NBR) Regions of The Gambia. The sample selection has
been described in detail elsewhere [13]. Briefly, 19 census
Enumeration Areas (EAs), which are designed to be of
approximately the same population size, were randomly selected
in LRR. A random selection of households was made so that 50
children aged under 10 years would be included. In Studies 2 and
3, all children aged under 10 years were included. Study 2 took
place in 6 Gambian communities and Study 3 in 12 Senegalese
communities. The Gambian communities were selected on the
basis of having a TF prevalence of at least 10% in the Gambian
survey [13], increasing the likelihood of finding infection. Study 3
was based in the health post of Keur Samba Kane in Bambey
District, which had been identified by the National Eye Care
Programme as fulfilling the WHO criteria for mass treatment.
Study 1 was conducted in January–March 2006, Study 2 in
March–May 2006, and Study 3 in January–February 2007.
Census enumeration
The village head (alkalo) and villagers were sensitised to the
study’s aims and methods. Household head lists were made and
the de facto population was enumerated, recording their name, alias
names, age and sex. Date-of-birth was noted when possible using
ID cards and infant vaccination cards. The census team identified
eligible children and informed household heads of the day and
place of examination to ensure optimum participation.
Clinical examination
Experienced Gambian and Senegalese graders were used. Their
grading was verified and standardised using WHO grading slides,
and a chance corrected agreement (Cohen’s kappa [14]) score of at
least 0.8 was required for the scoring of each sign (TF, TI, TS,
TT). NBR villages with the highest active trachoma prevalence in
the Gambian survey were re-visited and children diagnosed with
active disease were re-screened by a senior grader to verify clinical
diagnoses.
The examination team located itself in a central point in the
village. Eligible children were called and written informed consent
(signature or thumbprint) from the participants’ guardians was
obtained. The validated grader examined each consenting
participant’s eyes using a 2.56 magnifying loupe and torchlight.
In order to avoid cross-contamination, the examiner wore and
changed gloves between each participant. The clinical diagnosis
was made according to the WHO simplified grading system [2].
Ocular sample collection
Two swabs were taken from the tarsal conjunctiva of each
participant’s right eye using a standardised technique [15],
whereby the swab was held horizontally and drawn lengthways
across the everted upper tarsal conjunctiva four times, rotating the
head of the swab a quarter turn with each pass. Cross-
contamination of samples was limited by using a field worker to
pass the swab to the examiner. The field worker then held the tube
into which the swab would be stored dry, so that the examiner
never touched the tube, and the swab’s head only ever contacted
the participant’s conjunctiva.
In The Gambia, both samples were collected with the POC
test’s sterile polyurethane swab (Becton, Dickinson and Company,
Franklin Lakes, USA). In Senegal, the first sample was collected
with the POC test’s swab, and the second sample was with a dry
Dacron polyester-tipped swab (Quelab Laboratories, Montreal,
Canada). This swab change was because inhibition in Studies 1
and 2 was believed to be due to the polyurethane swab, as a cloudy
lysate was observed in the Amplicor extract.
Author Summary
Trachoma, caused by infection of the eye with the
bacterium Chlamydia trachomatis, is the leading infectious
cause of blindness and is associated with poverty.
Antibiotic treatment of all community members is one of
the recommended control strategies for trachoma. How-
ever, in places where the prevalence of clinical signs is low,
C. trachomatis eye infection is often absent. Laboratory
testing for C. trachomatis infection by polymerase chain
reaction (PCR) is highly sensitive but expensive and
requires well-trained staff. A simple point-of-care (POC)
test that can be used in trachoma-affected communities
could help trachoma control efforts. We evaluated a POC
test for C. trachomatis eye infection. Children under 10
years of age were screened for clinical signs of trachoma
and C. trachomatis eye infection. The POC test result was
compared with laboratory PCR test results. The POC test
detected just over half of PCR test positives correctly.
However, the POC test tended to give false-positive results
in hot and dry conditions, which is the typical environment
of trachoma. The POC test requires high specificity since it
would be used to make treatment decisions at the
community level. Therefore, its present format requires
improvement before it can be utilized in trachoma control.
Performance of Trachoma Point-of-Care Test
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POC test. The second-collected swabs, to later be tested for the
detection of ocular C. trachomatis with the qualitative PCR
Amplicor Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Test
(Roche Molecular Systems, Indianapolis, IN, USA), were stored in
a cool box in the field and archived frozen at 220uC within ten
hours of collection.
POC testing
POC testing was carried out according to the POC test’s
protocol [9]. Briefly, the eye swab was placed in a sample
preparation tube to which three reagents were added for the
release of Chlamydia LPS. Five drops of the sample extract were
transferred to a detection tube, rehydrating two lyophilised signal
amplification reagents. A dipstick was then placed inside the tube
and the mixture was left to wick up for 25 minutes before the
results were read.
The same person performed all POC testing and was masked to
the clinical diagnosis. Results were read at 25 minutes by two
different readers each masked to the other’s grading. The first
reader was trained by the Diagnostics Development Unit, and the
second reader was trained by the first reader. Grading was
practised on non-clinical samples prior to participant sample
collection. The signal strength was graded from 0 (negative) to 5
(strongly positive) using a signal grading card with increments of
0.5. A positive sample is defined as any signal with a signal
strength of 0.5 or more noted by the reader. In Senegal, a pocket
size temperature/humidity handheld datalogger (RH32 Series,
Omega, Manchester, UK) was used with values measured every
30 minutes.
Amplicor PCR processing
Amplicor, which detects the multi-copy cryptic plasmid, was
performed on the second-collected swab. Amplicor was chosen as
the reference test due to its good diagnostic performance on ocular
samples [16,17,18], its history of use for detection of ocular C.
trachomatis detection [15,19,20,21], and its use as the reference test
in the previous evaluation of this prototype POC test [9].
Study 1 samples were tested within 42 days of collection at the
Medical Research Council (MRC) Laboratories, Fajara, The
Gambia. About half of Study 2 samples were processed within 1
month at the MRC, and the remainder within 4 months at the
London School of Hygiene & Tropical Medicine (LSHTM). All
Senegalese samples were processed at the LSHTM between 2
and 6 months of collection. A previously published [15] sample
preparation protocol was used instead of that in the Amplicor
package insert. Positive and negative controls provided with the
assay were included to validate the runs. When clusters of
positives were observed on the detection plate, the positive
samples were retested on-site. Those confirmed positive on the
retest were considered Amplicor positives, and the others were
considered negatives. Amplification of both the plasmid DNA
and the master-mix internal control sequence was tested, allowing
for inhibition to be detected. Inhibited samples were diluted from
1/5 up to 1/100 with a 50:50 lysis:diluent mix, until inhibition
was resolved.
Figure 1. Flowchart outlining study methods and results.
doi:10.1371/journal.pntd.0001234.g001
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The bacterial load of Amplicor positive samples was estimated
by processing the samples with a real-time quantitative PCR assay
targeting the single-copy ompA gene [15]. The reverse primer,
common to all ocular serovars, was 59-TTT AGG TTT AGA
TTG AGC ATA TTG GA-39. The serovar A and B forward
primers were 59-GCT GTG GTT GAG CTT TAT ACA GAC
AC-39 and 59-TCT GTT GTT GAG TTG TAT ACA GAT AC-
39 (Sigma-Genosys, Gillingham, UK), respectively. Quantitation
was done on two 4 mL replicate samples for both serovar A and
serovar B. The Gambian samples were processed in a LightCycler
(Roche Diagnostics, Indianapolis, USA). The Senegalese samples
were processed on a Rotor-Gene RG3000 (Qiagen, Crawley, UK).
Quality control
Protocol changes were introduced as the study progressed to
help ensure data quality. These changes involved the introduction
of a POC test panel to be performed in the field, mock swabs
inserted between patient samples in the field, environmental
controls (air, loupe and glove swabs), and testing for laboratory
contamination.
Panel. For Studies 2 and 3, a panel of positive (low, medium
and high concentrations of C. trachomatis LGV-L1) and negative
controls was processed at the beginning of each working morning
and afternoon to check that the POC test was working correctly. A
swab was dipped into the control vial (for the negative control:
10 mM PBS, 0.1% sodium azide and 1% treated casein;
concentrations for the positive controls which should all be POC
test positive: High: 1.143610
7 C. trachomatis elementary bodies
(EB)/ml; Medium: 9610
5 EB/ml; Low: 2.25610
5 EB/ml) and
processed normally. Before the addition of the third reagent,
50 mL of these controls was aliquoted into 200 mL of pre-dispensed
Amplicor diluent to be later processed by Amplicor, to serve as
negative and positive controls from the field to the laboratory.
These aliquoted panels were stored in the same way as the ocular
swabs.
In Senegal, two types of field sample control were introduced:
Environmental controls. At approximately every
hundredth sample, a swab was waved in the air (air control),
another swab wiped the top of the glove box (glove control), and a
third swab wiped the front of the loupe (loupe control).
Mock swabs. Pre-prepared mock swabs were introduced
between patient samples in the field before POC testing. Positive
swabs were prepared with a non-ocular C. trachomatis strain (LGV-
L1). The low load positive was below the POC test detection limit
(2500 chlamydial EBs per test [9]) and the high load positive was
above the detection limit. Negative mock swabs were also
included. Mock swabs were introduced at a frequency which
meant that one of each type of specimen would be processed per
89 patient samples. The samples were labelled in the same way as
normal swabs to mask the POC and Amplicor test processors.
Amplicor quality control. At both LSHTM and MRC,
Amplicor was conducted by experienced laboratory staff who had
successfully completed a masked panel of samples. The Amplicor
processors were masked to the clinical diagnoses and POC test
results. As a measure of Amplicor reproducibility, the Amplicor-
positive samples from Study 2 (20 tested at MRC, 15 tested at
LSHTM) were re-tested by Amplicor at the University of
Cambridge, and 21 Amplicor-negative samples were re-tested at
LSHTM by a scientific officer who did not know the samples’
origin. As part of the ongoing improvement to quality assurance
throughout the study, it was decided to check for laboratory
contamination at the time of processing the Senegalese samples.
Swabs were taken of the laboratory cabinet surfaces and gloves,
and processed by Amplicor.
To verify the quality of sample collection, Study 1 samples were
tested for the presence of human-specific hypervariable 1 (HV1)
D-loop region mitochondrial DNA (mtDNA) [13]. mtDNA-
positive results indicate that human DNA is present in the sample.
Statistical analyses
Results were double-entered by different entry clerks and
verified in Microsoft Access (MS Access v2000/2003XP). Any
discrepancies after verification were checked against the original
paper forms. Data cleaning was performed in Stata (v9.2, STATA
Corp., College Station, TX, USA).
Data analysis was performed in Stata, except for the humidity
and temperature analyses which were performed in R (v 2.9.0, R
Foundation for Statistical Computing, Vienna, Austria). As a result
of the change in Amplicor swab type between Studies 2 and 3, and
that the graders in The Gambia and Senegal were different, results
from the 3 studies have not been combined.
The kappa statistic was used to assess between-grader
agreement for the POC test and to assess Amplicor reproducibil-
ity. The performance (sensitivity, specificity, Positive Predictive
Value (PPV) and Negative Predictive Value (NPV)) of the POC
test was compared against Amplicor as the gold standard.
Binomial exact 95% confidence intervals (CI) were calculated to
quantify uncertainty. Proportions were compared using Pearson’s
chi-squared statistic. Cuzick’s trend test was used to look at the
relationship between quantitative load, clinical sign status and
POC test result.
The effect of temperature and humidity on the POC test’s
performance was measured using logistic regression. A scatter plot
of false-positives (FPs) and true-negatives (TNs) by temperature
and humidity was made, with contours of the relative risk of FPs
relative to TNs. For each TN, a bivariate Normal density function
was centred on the corresponding point. At any point on the
graph, a density for TNs was calculated by summing these
individual densities. A similar procedure was applied to the FP
results. At any point, the relative risk is the ratio of these two
densities. Contours of this relative risk were then added to the
scatter plot (Figure 2).
Figure 2. Relative risk of false-positives relative to true-
negatives by temperature and relative humidity for Study 3.
doi:10.1371/journal.pntd.0001234.g002
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A total of 3734 children were screened and tested. Study 1
(LRR, The Gambia) included 950 children under 10 years, Study
2 (6 villages, The Gambia) 1171, and Study 3 (Senegal) 1613. This
represents participation of 88.3% (950/1076), 90.8% (1171/1289),
and 96.6% (1613/1669) based on the censused population in
Studies 1, 2, and 3, respectively.
Laboratory controls
During Amplicor processing of the Senegalese samples, 12 lab
controls were taken to check for lab contamination (3 for the hood,
2 of the glove box, 2 of the cabinet, and 5 of the gloves). All were
Amplicor-negative.
Mock swabs
In Senegal, 14 negative, 15 low load, and 11 high load mock
swabs were introduced in between patient samples. Amplicor
correctly detected all results. For the POC test, the number of
correctly identified negative, low and high load positive cases
differed significantly for reader 1 (p=0.007) and reader 2
(p=0.004). For both readers, the POC test correctly detected
the high load positives in 100% of cases. These had a signal
strength ranging from 1.0 to 2.0 for reader 1, and from 1.0 to 2.5
for reader 2. For low load positives (that tested POC negative
under standard laboratory conditions), 5 samples were graded as
positive by both the first and second readers. An additional sample
was graded positive by reader 1, and 3 other samples as positive by
reader 2. Thus, a total of 9/15 low load positives were detected by
the POC test in the field. The signal strength of these false-
positives ranged from 0.5 to 1.5 for both readers. For the negative
controls, the readers both graded 5 samples as positive, and reader
2 additionally graded 4 samples as positive. These false-positives
had signal strengths of 0.5 or 1.0 for both readers.
Environmental controls
In Senegal, there were 16 air controls, 16 glove controls, and 17
loupe controls. All were Amplicor negative. Less than half the
POC test results were negative for both reader 1 (42.9%) and
reader 2 (46.9%).
POC test panel
In total, there were 101 panel positive and negative controls
aliquoted in the field and tested by Amplicor (52 in Study 2 and 49
in Study 3). All 63 positive controls were correctly detected by
Amplicor. Of the 38 negative controls, one from The Gambia
tested positive repeatedly and two initially tested equivocal but
were negative when repeat tested in duplicate. There was an
additional equivocal negative control result by Amplicor, but the
sample was erroneously labelled only as ‘‘negative control’’ on the
template, without specifying which negative control this was,
meaning it could not be retested.
A total of 56 panels were tested by the POC test (14 in Study 2
and 42 in Study 3). All positive panels, regardless of concentration,
were positive by the POC test for both readers. The proportion of
all negative panels correctly recorded as negative by the POC test
was 60.7% for reader 1 (85.7% for Study 2, 52.4% for Study 3),
and 66.1% for reader 2 (92.9% for Study 2 and 57.1% for Study
3).
Sample quality
Of 942 Amplicor-negative samples for which sample was
available in Study 1, positive results for human-specific hyper-
variable D-loop region mtDNA were obtained in 937 (99.5%)
samples. The five mtDNA-negative samples and five samples that
could not be tested for mtDNA because of insufficient material
from Study 1 have been removed from analyses. Three field air
controls were randomly selected and also tested for C. trachomatis
and human mtDNA, and provided negative results.
Inhibition by swab type
Inhibition in Studies 1 and 2 which used the POC test
polyurethane swab was 23.4% (220/940) and 22.8% (2671171),
respectively. The proportion of inhibited samples in Study 3 was
18.2% (293/1613), so the change of swab did not make a
noticeable difference to the level of inhibition. Only one inhibited
sample, from Study 2, retested as Amplicor positive.
Amplicor reproducibility
Of the 35 Amplicor-positive samples from Study 2 retested at
the University of Cambridge, 27 were confirmed positive (23 as
positive and 4 as equivocal), 3 were negative but failed the Internal
Control (IC), and 5 were negative and passed the IC. All 21
Amplicor-negatives retested as negative. These retests resulted in a
kappa score between the initial and retest results of 0.73,
demonstrating substantial agreement.
All 35 samples originally tested as positive were considered true
positives for the analyses presented. Of the 5 negatives, three were
positive by quantitative PCR with estimated loads of 5, 7 and 25
ompA copies/swab. The remaining two positives were isolated
among a string of negatives in the field, and were not near positive
samples on the Amplicor detection plate.
If a true positive was considered to be one that was positive at
both LSHTM and the University of Cambridge (27 samples
retested positive or equivocal), the specificity and PPV estimates
remain the same. The NPV increases slightly to 98.7% (97.9–99.3)
for reader 1 but decreases to 98.8% (98.0–99.4) for reader 2. The
sensitivity increases for both readers, but insignificantly: 48.1%
(28.7–68.1, p=0.384) for reader 1 and 51.9% (31.9–71.3,
p=0.352) for reader 2.
Repeat of Amplicor positive samples clustered on the
detection plate
For Study 1, none of the 3 Amplicor positives were retested. For
Study 2, 10/39 Amplicor positives were retested, and 6 retested
negative. For Study 3, 13/51 Amplicor positives were retested and
all retested positive.
Diagnostic performance
The prevalence of active trachoma and Amplicor positives was,
respectively, 11.9% and 0.3% in Study 1, 23.9% and 3.0% in
Study 2, and 14.9% and 1.8% in Study 3. During field processing
of the POC test, mistakes were made for 4 samples in Study 1, and
3 samples in Study 3. These samples have been removed from
analyses involving the POC test. The POC test’s sensitivity,
specificity, PPV and NPV against Amplicor showed similar point
estimates and 95% CI for the two readers (Table 1). Overall,
sensitivity and PPV were low, with respective estimates ranging
from 33.3%–67.9%, and 4.3%–21.0%. The specificity met the
minimum target of 98% in Study 1, but not in Studies 2 or 3.
There is no evidence of a significant difference between the
point estimates and corresponding 95% CI for NPV, PPV, or
sensitivity between the three studies. Precision for the sensitivity
estimates was low due to small numbers (Table 1). Compared with
Study 1, the specificity of the POC test was significantly lower in
both Study 2 (p,0.001) and Study 3 (p=0.001). In Studies 2 and
3, the specificity upper confidence bounds did not exceed 96.8%.
Performance of Trachoma Point-of-Care Test
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performance
Temperature and relative humidity data were collected for all
samples from Study 3 (1584 Amplicor-negatives and 29 Amplicor-
positives). Figure 2 shows contours of the relative risk (RR) for FPs
relative to TNs, with shading from green to red as the RR
increases (see under Statistical Analyses in the Methods section). It
is apparent that the false-positive RR began to increase at
temperatures above 30uC and at relative humidities below 10%.
The RR of a FP is approximately three times that of a true-
negative at a temperature of about 36uC and at a relative humidity
of 10%, and increases more rapidly as temperature rises and
humidity falls.
Plots of FP rates against temperature and relative humidity
indicated an increase at temperatures above 31.4uC, and a relative
humidity below 11.4%. Estimates of diagnostic accuracy calculat-
ed for samples processed above and below the 31.4uC temperature
threshold showed that the specificity was significantly lower in
samples processed above the threshold than below, for both the
first and second POC test readers (p,0.001) (Table 2). For
humidity, the specificity was significantly lower in samples
processed below a threshold of 11.4% compared with those above
the threshold, for both readers (p,0.001) (Table 2).
Analytic sensitivity of the POC test
Of the 67 Amplicor-positives, positive ompA results were
obtained in 58 (86.6%) samples by quantitative PCR. The
estimated number of ompA copies/swab ranged from 5 to
3,008,063, with a median of 670. Although a few low load PCR
positives were POC test positive, the POC test consistently
detected positives from 1000 ompA copies/swab. Although the
POC test is a qualitative assay, the signal strength was scored on a
scale from 0.5 (weak) to 5.0 (strong) in the field. There was a
significant association between increased organism load and
increased POC test signal strength (p,0.001).
Inter-grader agreement
The kappa score for inter-grader variability between the two
POC test readers was lowest for Study 1 and highest for Study 3.
For exact signal strength the kappa score ranged from 0.41 to 0.59,
showing moderate agreement. When the results were categorised
as positive (signal strength $0.5) or negative (signal strength ,0.5),
the scores ranged from 0.26 to 0.68, demonstrating fair to
substantial agreement.
Discussion
In this study we conducted an evaluation of a prototype POC
test for the detection of ocular C. trachomatis in children aged under
10 years in The Gambia and Senegal. After following standardised
field and laboratory protocols, ensuring quality assurance and data
validity, the results demonstrated that in its present format, this
POC test is not suitable for use in the field. Under laboratory
conditions, the negative and low positive mock swabs resulted in
negative POC tests. In the field, the POC test gave false-positive
results for approximately half of these mock swabs. This
demonstrates that the POC test does not pass quality control
procedures when tested in the field. When tested on children’s
ocular swabs, specificity in Study 1 was excellent (99.0% and
97.6% for readers 1 and 2, respectively). This is consistent with the
specificity reported from the previous evaluation of this test
performed in Tanzania, where the overall specificity was 99.4%
(95%CI 98.8–100) [9]. However, in Studies 2 and 3, the specificity
ranged from 92.4% to 95.7%, falling short of the 98% minimum
specificity required for this test.
The temperature and relative humidity data provide the most
likely explanation for the lower POC test specificity in Studies 2
and 3. Study 1 was conducted in January and February, when The
Gambia is experiencing its cool season. Study 2 took place just
before the rainy season, when temperatures rise. In Study 3, high
temperatures and low relative humidities were recorded whilst
performing the test, and these conditions were shown to
significantly affect the false positive rate of the POC test. These
data indicate that the prototype POC test’s format is not
appropriate for these environmental conditions.
Evaluations of rapid POC tests for other infectious diseases have
observed a detrimental effect of high temperature and humidity
during test storage on performance [22,23,24]. However, we
observed an effect on the test’s performance in the field during
processing. A review of malaria rapid diagnostic tests which also
use lateral flow technology, notes that humidity and wind rapidly
degrade nitrocellulose capillary flow action. This effect on reagent
Table 1. Diagnostic accuracy of the POC test compared with the gold standard (Amplicor).
PCR POC test - reader 1 POC test - reader 2
Negative Positive Total Negative Positive Total
Study 1 Negative 927 6 933 911 22 933
Positive 2 1 3 2 1 3
Total 929 7 936 913 23 936
Negative Positive Total Negative Positive Total
Study 2 Negative 1087 49 1136 1076 60 1136
Positive 22 13 35 21 14 35
Total 1109 62 1171 1097 74 1171
Negative Positive Total Negative Positive Total
Study 3 Negative 1461 121 1582 1492 90 1582
Positive 9 19 28 11 17 28
Total 1470 140 1610 1503 107 1610
doi:10.1371/journal.pntd.0001234.t001
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time could be detrimental to the test’s sensitivity, as they have been
reported to deconjugate the signal line antibody-indicator
complex, detach the capture antibody from the nitrocellulose
strip, and unfold the binding sites of antibodies [25]. Since the
dipstick of the ocular C. trachomatis POC test under evaluation is
made up of a nitrocellulose membrane transversely lined with
mAb against chlamydial LPS and antibiotin, these are plausible
explanations for the observed deleterious effect of high temper-
ature and low relative humidity on the test’s performance. These
results suggest that the environmental conditions during Studies 2
and 3 were harsher than those experienced in Study 1 and
Tanzania, and emphasise the importance of conducting POC test
evaluations in different settings. A change in the format of the
prototype POC test that prevents its performance from being
affected by the dry, hot, and dusty environments in which
trachoma is predominantly found [26], would no doubt improve
the usefulness of this test for trachoma control.
False-positives may also have appeared as a result of the POC
test’s target being the genus-specific chlamydial LPS. We do not
believe, however, that cross-reaction with non-C. trachomatis
bacteria was the cause of the POC test false-positives observed
in this study. As noted by Michel et al., the POC test’s specificity
has been established against a panel of microorganisms commonly
associated with the human eye and skin (such as Staphylococcus,
Pseudomonas, Streptococcus, Escherichia, Proteus, and Candida, obtained
from ATCC) [9]. In addition, if cross-reaction were taking place, it
would not explain the observed association between FPs with
temperature and humidity.
The advantage of testing the prototype POC test in low
prevalence settings was the ability to gain a good estimate of
specificity. The disadvantage is that we have been unable to
determine an accurate estimate of the test’s sensitivity. In
addition, the active disease found in this study was mild with
only 6.5% of clinically active children having TI. Infection load is
correlated with disease severity [4,15,27]. The consequence of
lower infection loads is a lower test sensitivity, especially in an
assay that detects a surface antigen as opposed to one using PCR
technology. Indeed, the Tanzanian evaluation observed a lower
(albeit non-significant) sensitivity (76.9%) of the POC test in the
lower prevalence site (TF prevalence 12.5%) compared with a
sensitivity of 85.5% where the TF prevalence was 31.5% [9].
Michel et al. (2006) noted that the assay has an analytical
sensitivity of 2500 chlamydial EBs per test [9]. Our quantification
demonstrated consistent detection from approximately 1000 ompA
copies/swab.
Table 2. Effect of temperature and humidity on performance of the POC test compared to Amplicor PCR.
Temperature threshold: 31.46C
POC test – reader 1 POC test – reader 2
Below threshold Above threshold Below threshold Above threshold
True positive 10 9 10 7
True negative 956 505 961 531
False positive 21 100 16 74
False negative 7 2 7 4
Sensitivity 58.8
(32.9–81.6)
81.8
(48.2–97.7)
58.8
(32.9–81.6)
63.6
(30.8–89.1)
Specificity 97.9
(96.7–98.7)
83.5
(80.3–86.4)
98.4
(97.4–99.1)
87.8
(84.9–90.3)
PPV 32.3
(16.7–51.4)
8.3
(3.8–15.1)
38.5
(20.2–59.4)
8.6
(3.5–17.0)
NPV 99.3
(98.5–99.7)
99.6
(98.6–100)
99.3
(98.5–99.7)
99.3
(98.1–99.8)
Relative humidity threshold: 11.4%
POC test – reader 1 POC test – reader 2
Below threshold Above threshold Below threshold Above threshold
True positive 6 13 5 12
True negative 381 1080 403 1089
False positive 90 31 68 22
False negative 2 7 3 8
Sensitivity 75
(34.9–96.8)
65
(40.8–84.6)
62.5
(24.5–91.5)
60
(36.1–80.9)
Specificity 80.9
(77.0–84.3)
97.2
(96.1–98.1)
85.6
(82.1–88.6)
98
(97.0–98.8)
PPV 6.3
(2.3–13.1)
30.2
(17.2–46.1)
6.8
(2.3–15.3)
35.3
(19.7–53.5)
NPV 99.5
(98.1–99.9)
99.4
(98.7–99.7)
99.3
(97.9–99.8)
99.3
(98.6–99.7)
Values in parentheses are 95% CI.
doi:10.1371/journal.pntd.0001234.t002
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to 6 months between sample collection and sample processing,
which could have resulted in low load positives testing negative.
This may have contributed to the number of POC test false-
positives observed. However, since samples were stored at 220uC,
we do not believe that the DNA would have degraded and that
waiting would have led to a decrease in the number of true
positives.
The POC test was performed on the first-collected swab
whereas the ‘‘gold standard’’ Amplicor testing was on the second-
swab. There may be differences between the two swabs, for
example, in cases where there are few EBs in the conjunctiva the
first swab may not leave any for the second swab. One of the
swabs may also collect more PCR-inhibiting material, such as
mucous, resulting in inhibition in one of the assays. Furthermore,
one swab may be passed more forcefully over the conjunctiva,
collecting more DNA or inhibiting material. Michel et al. (2006)
demonstrated that first-collected swabs had higher loads than
second-collected swabs by comparing organism load in the first-
and second-collected swabs from 13 Amplicor positive individ-
uals. The first swab’s mean EB count was 643,424 compared with
181,310 for the second swab. This should not affect the Amplicor
prevalence as its detection level is in the range of 1–10 EBs
[28,29]. Furthermore, Amplicor result concordance between first-
and second-collected swabs has been shown to be excellent
[5,30].
There was a change in swab type between Study 2 and Study
3 because it was believed that the polyurethane swab led to
inhibition. However, the swab change did not make a noticeable
difference to the level of inhibition. The disadvantage of
inhibition is the need to dilute the sample, which would reduce
the copy number in any sample tested, resulting in Amplicor
false-negatives. Since load of infection in the study sites was
often low (with 37.3% of all Amplicor positives having a load of
,10 ompA copies/swab or being negative), this is a distinct
possibility, and could have contributed to the low specificity of
the POC test.
Another possible limitation is our choice of gold standard. In
the absence of a universally accepted gold standard for C.
trachomatis, we chose Amplicor as it was used in the previous
evaluation of this POC test [9], and it has been used in multiple
s t u d i e so fo c u l a rC. trachomatis infection. Controls included to
assure the quality of our gold standard produced excellent results.
Air, loupe, glove and spiked mock swab field controls were all
correctly identified. The Amplicor results for aliquots from the
POC test control panel were correct except for one negative
panel from Study 2, which was repeatedly positive, and one
equivocal which could not be repeat tested because the sample
name was not correctly written on the Amplicor plate template.
This suggests contamination of the negative panel from the
positives when aliquoting in the field, which is possible as
stringent laboratory conditions cannot be maintained in such an
environment. Furthermore, it was a requisite for a successful run
that the Amplicor-provided positive and negative controls
processed for each plate produce the correct result, indicating
that contamination in the lab is unlikely. This is supported by the
Amplicor negative results of swabs taken of lab surfaces to check
for lab contamination. When positives clustered on the detection
plate were repeat tested, 6/10 retested samples from Study 2
retested negative. This could indicate that there was contamina-
tion between the wells on the detection plate, and for this reason
they were considered negative in analyses. Alternatively, these
samples could have been low load positives that did not repeat
test positive. Of the 35 Amplicor positives retested by Amplicor at
the University of Cambridge, five tested negative.. The failure to
retest these five samples as positive was not unexpected as
reproducibility when retesting the original sample with the same
test is known to be poor for low load samples [31,32,33,34,35,36].
However, when samples that were not repeated positive at the
University of Cambridge were removed from the analyses, there
was no significant effect on the prototype POC test’s perfor-
mance.
The development of effective diagnostic tools is considered a
priority for Neglected Tropical Diseases (NTDs) [37], and it is
t h e r e f o r ei m p o r t a n tt ob ea w a r eo ft h ei m p a c tt h ee n v i r o n m e n t
c a nh a v eo nt h eo p e r a t i o n a lp e r f o r m a n c eo fP O Ct e s t s .Al a t e r a l
flow platform in an open system appears not to be suitable for
the environments in which NTDs, such as trachoma, are often
found. A rapid, accurate, simple, and affordable POC test which
can be performed in the field could be a great asset to trachoma
control, particularly in low prevalence settings. The specificity of
t h et e s tm u s tb eh i g h( .98%) to prevent communities from
being unnecessarily mass treated. The specificity of the
prototype POC test evaluated in this study decreased as the
temperature increased and relative humidity decreased, indi-
cating the importance of field testing POC tests in the different
environments in which the target disease is found, in addition to
being evaluated in different prevalence settings. Until a suitable
test is made available, trachoma control decisions in the field
remain reliant on clinical diagnosis, potentially wasting scarce
resources.
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